Erasmus School of Health Policy & Management
Endowed professor | Health Technology Assessment (HTA)
- retel@eshpm.eur.nl
More information
Work
- Joost G.E. Verbeek, Rianne L. Seefat, Erica A. Wilthagen, Agnes Jager, Sabine C. Linn, Valesca P. Retèl & Wim H. van Harten (2026) - Coverage with evidence development programs: a scoping review on characteristics and patient access - Health Policy, 171 - doi: 10.1016/j.healthpol.2026.105615 - [link]
- Rianne L. Seefat, Sonja B. Vliek, Vincent M.T. de Jong, Sara Balduzzi, Ingrid A. Mandjes, Valesca P. Retèl, Inge Eekhout, Marjolein Delfos, Margaret Schot, Marjo J. Holtkamp, Mandy M. van Rosmalen, Brenda Leeneman, Hedwig Blommestein, Alwin D.R. Huitema, Efraim H. Rosenberg, Petra M. Nederlof, Terry W.S. Chan, Anna van Rhenen, Marielle J. Wondergem, Nicolaas P.M. Schaap, Tjeerd J.F. Snijders, Marjolein W.M. Van der Poel, Wouter J. Plattel, Erik van Werkhoven, Harm van Tinteren, Marjolein L. Smidt, Jelle Wesseling, Jos Jonkers, Sven Rottenberg, Marie Jeanne T.F.D. Vrancken Peeters, Carlijn Voermans, John H. Maduro, Judith R. Kroep, Carolien P. Schroder, Evelien J.M. Kuip, Anthony Gonçalves, Janine Nuver, A. N.Machteld Wymenga, Rhodé M. Bijlsma, Elsken van der Wall, Inge R.H.M. Konings, Vivianne C.G. Tjan-Heijnen, Mojca Jongen-Lavrencic, Agnes Jager & Sabine C. Linn (2026) - Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial - The Lancet Oncology, 27 (7), 795-807 - doi: 10.1016/S1470-2045(26)00131-2 - [link]
- N. Franzen, J. Vancoppenolle, V. P. Retèl, S. Vogler & W. H. van Harten (2026) - A comparative analysis of managed entry agreements in Europe: trends, reporting practices, and financial outcomes - European Journal of Health Economics - doi: 10.1007/s10198-026-01942-3 - [link]
- Jasper Ubels, Julie M. Vancoppenolle, Josephine Tetteh, Wim H. van Harten, Valesca P. Retèl, Michael Schlander & Nora Franzen (2026) - Toward a validated European instrument to measure the socioeconomic impact of cancer - International Journal of Cancer, 158 (12), 3288-3299 - doi: 10.1002/ijc.70364 - [link]
- Julie Vancoppenolle, Nora Franzen, Cristina Andrianò, Morten Baltzer Houlind, Zora Ćetković, Aniek Dane, Albane Degrassat-Théas, Anne M.P. Eldering-Heldens, Martin J. Hug, Holger Knoth, Vito Ladisa, Péter Vajda, Ulrich Warnke, Valesca Retèl & Wim H. van Harten (2026) - Price transparency of cancer medicines: a crucial step towards informed pricing negotiations in the European region - Frontiers in Pharmacology, 17 - doi: 10.3389/fphar.2026.1736741 - [link]
- Zainab Al-Khayat, Nora Franzen, Valesca P. Retèl & Wim H. Van Harten (2025) - Hospital-based real-world evidence in health technology assessment: insights from a scoping review of European, Australian and North American guidance and expert interviews - BMJ open, 15 (12) - doi: 10.1136/bmjopen-2025-100304 - [link]
- Madelief Schreuder Goedheijt, Ruby M. van Stein, Simone N. Koole, Gabe S. Sonke, Willemien J. van Driel & Valesca P. Retèl (2025) - Budget Impact Analysis of Hyperthermic Intraperitoneal Chemotherapy With Interval Cytoreductive Surgery in Ovarian Cancer - JCO Oncology Practice, 88 - doi: 10.1200/OP-25-00670 - [link]
- Lucas F. van Schaik, Brigitte Maes, Pieter Jan Volders, Guy Froyen, Philippe Aftimos, Evandro de Azambuja, Hedwig M. Blommestein, Wim H. van Harten & Valesca P. Retèl (2025) - Economic Evaluation of Comprehensive Genomic Profiling in an Advanced Solid Cancer Population - JAMA network open, 8 (12) - doi: 10.1001/jamanetworkopen.2025.48538 - [link]
- Sabine E. Breukers, Joleen J.H. Traets, Stan W. van Dijk, Mercedes Machuca Ostos, Itske Fraterman, Robert D. Crommelin, Hedda van der Hulst, Xiaohang Qiao, Thomas Boere, Lonneke V. van de Poll-Franse, Valesca Retèl, Vincent van der Noort, Joris L. Vos, Alexandra G.L. Toppenberg, Martijn van der Heijden, Francesco Missale, Fons Balm, Michiel van den Brekel, Richard Dirven, M. Baris Karakullukcu, Luc Karssemakers, W. Martin C. Klop, Peter J.F.M. Lohuis, Willem H. Schreuder, Ludi E. Smeele, Lilly Ann van der Velden, Elsemieke Plasmeijer, Laura A. Smit, Jan Paul de Boer, Arash Navran, Bram Westerink, Petra K. de Koekkoek-Doll, Jonas Castelijns, Maurits Wondergem, Wouter V. Vogel, Anke Kuijpers, Winan J. van Houdt, Suzanne Onderwater, Esther Maas-Bannink, Sten Cornelissen, Annegien Broeks, Bernard M. Tijink, Lot A. Devriese, Remco de Bree, Christian U. Blank, Ton N. Schumacher, Daniela S. Thommen, John B.A.G. Haanen & Charlotte L. Zuur (2025) - Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial - Nature Medicine, 31 (12), 4055-4064 - doi: 10.1038/s41591-025-03943-w - [link]
- Julie M. Vancoppenolle, Silvie H.M. Janssen, Nora Franzen, Winette T.A. van der Graaf, Valesca Retel, Olga Husson & Wim van Harten (2025) - Socioeconomic impact among and socioeconomic support services for adolescents and young adults with cancer: A European perspective - International Journal of Cancer, 157 (7), 1433-1445 - doi: 10.1002/ijc.35488 - [link]
Health Economics Organisation European Cancer Inst
- Start date approval
- september 2021
- End date approval
- december 9999
- Place
- BRUSSEL
- Description
- Coordinator werkgroep
KWF
- Start date approval
- september 2021
- End date approval
- december 9999
- Place
- ROTTERDAM
- Description
- Lid beoordelingscommissie
NKI-AVL Amsterdam
- Start date approval
- september 2021
- End date approval
- december 9999
- Place
- AMSTERDAM
- Description
- Hoofd afdeling Health Technology Assessment
ZonMW
- Start date approval
- september 2021
- End date approval
- december 9999
- Place
- DEN HAAG
- Description
- Lid beoordelingscommissie
Master Thesis HEPL
- Level
- master
- Year Level
- master
- Year
- 2025
- Course Code
- GW4555M
Master Thesis Eu-HEM
- Level
- master
- Year Level
- master
- Year
- 2025
- Course Code
- GW4560M
Master Thesis HE
- Year Level
- master, master
- Year
- 2025
- Course Code
- GW4592M
